Volume 5.32 | Aug 26

Hematopoiesis News 5.32 August 26, 2014
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HN on Twitter
 
TOP STORY
Natural (Born) Killer Cells Battle Pediatric Leukemia
Researchers have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that can be used to destroy the cancer cells. [Press release from Children’s Hospital Los Angeles discussing publication in Leukemia] Press Release | Abstract
Free Poster: Quick Reference for Mouse Immune Cell Frequencies and Percentages
 
PUBLICATIONS (Ranked by impact factor of the journal)
The DPY30 Subunit in SET1/MLL Complexes Regulates the Proliferation and Differentiation of Hematopoietic Progenitor Cells
Researchers show that DPY30, a shared core subunit of the SET1/MLL family methyltransferase complexes and a facilitator of their H3K4 methylation activity, is important for ex vivo proliferation and differentiation of human CD34+ hematopoietic progenitor cells. [Blood] Abstract

Runx1 Is Required for Progression of CD41+ Embryonic Precursors into HSCs but Not Prior to This
Scientists report that Runx1 deficiency does not preclude formation of VE-cad+CD45CD41+ cells, which are phenotypically equivalent to precursors of definitive hematopoietic stem cells (HSCs) but blocks transition to the subsequent CD45+ stage. [Development] Full Article

IL-33-Induced Hematopoietic Stem and Progenitor Cell Mobilization Depends upon CCR2
Researchers analyzed the in vivo effect of IL-33 administration. IL-33 markedly promoted myelopoiesis in the bone marrow and myeloid cell emigration. [J Immunol] Abstract

The Effects of 1,25-Dihydroxyvitamin D3 on In Vitro Human NK Cell Development from Hematopoietic Stem Cells
1,25-Dihydroxyvitamin D3 strongly induced hematopoietic stem cells to differentiate along a myeloid pathway, giving rise to CD14+ cells. [J Immunol] Abstract

RIP3 Is Downregulated in Human Myeloid Leukemia Cells and Modulates Apoptosis and Caspase-Mediated p65/RelA Cleavage
Researchers analyzed the expression of receptor-interacting protein kinase (RIP)1 and RIP3 in CD34+ leukemia cells from a cohort of patients with acute myeloid leukemia (AML) and CD34+ cells from healthy donors. RIP3 expression was significantly reduced in most AML samples, whereas the expression of RIP1 did not differ significantly. [Cell Death Dis] Full Article

The Corepressor Tle4 Is a Novel Regulator of Murine Hematopoiesis and Bone Development
Tle4 deficient hematopoietic stem cells are intrinsically defective in B lymphopoiesis and exhaust upon stress, such as serial transplantation. In the absence of Tle4 there is a profound decrease in bone mineralization. In addition, Tle4 knockout stromal cells are defective at maintaining wild-type hematopoietic stem cell function in vitro. [PLoS One] Full Article

CLINICAL RESEARCH

Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
Silent cerebral infarcts are the most common neurologic injury in children with sickle cell anemia and are associated with the recurrence of an infarct (stroke or silent cerebral infarct). Scientists tested the hypothesis that the incidence of the recurrence of an infarct would be lower among children who underwent regular blood-transfusion therapy than among those who received standard care. [N Engl J Med] Abstract | Press Release

Good Outcome of Haploidentical Hematopoietic SCT as a Salvage Therapy in Children and Adolescents with Acquired Severe Aplastic Anemia
A total of 17 children and adolescents with severe aplastic anemia underwent haploidentical hematopoietic SCT. The conditioning regimen consisted of BU, fludarabine, CY and anti-thymocyte globulin. [Bone Marrow Transplant] Abstract

Early CMV Replication and Subsequent Chronic GvHD Have a Significant Anti-Leukemic Effect after Allogeneic HSCT in Acute Myeloid Leukemia
Univariate analysis revealed that the factors associated with a reduction in the 5-year cumulative incidence of relapse included the first complete remission status at allogeneic hematopoietic stem cell transplantation (HSCT), non-adverse cytogenetics and molecular abnormalities, pre-transplant serum ferritin level <1,400 mg/dl, chronic graft-versus-host disease (GvHD), and early cytomegalovirus replication. [Ann Hematol] Abstract

[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
 
REVIEWS
The Role of Telomeres and Telomerase in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
The characteristics and roles of telomeres and telomerase both in hematologic malignancies and in hematopoietic stem cell transplantation are summarized. The current status of telomerase-targeted therapies utilized in the treatment of hematologic malignancies are also reviewed. [J Hematol Oncol] Full Article

Pro-inflammatory Cytokines: Emerging Players Regulating HSC Function in Normal and Diseased Hematopoiesis
The authors highlight key advances demonstrating the impact of pro-inflammatory cytokines on the biology of hematopoietic stem cells (HSCs) and the bone marrow niche, and address ongoing questions regarding their role in normal and pathogenic hematopoiesis. [Exp Cell Res] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

BioProcess International Conference & Exhibition - Boston MA
 
INDUSTRY NEWS
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Gamida Cell announced that it has signed an investment and option agreement with Novartis Pharma AG. Gamida Cell is currently engaged in a Phase I/II study of NiCord® as an investigational therapeutic treatment for hematological malignancies such as leukemia and lymphoma. [Gamida Cell] Press Release

Cancer Genetics, Inc. and Leading Pathologist from Keck Medicine of USC Collaborate to Evaluate and Optimize Genomic Panel for Lymphoma
Cancer Genetics, Inc. and Keck Medicine of the University of Southern California (USC) pathologist Imran Siddiqi, M.D., Ph.D., announced that they have entered into a collaboration to identify and evaluate genomic markers for the prognosis of diffuse large B-cell lymphoma. [Cancer Genetics, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW European Multiple Myeloma Academy 2014 (EMMA 2014)
September 26-27, 2014
Vienna, Austria

Visit our events page to see a complete list of events in the hematopoiesis community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Positions – Hematopoietic and Induced Pluripotent Stem Cells (Indiana University School of Medicine)

NEW Postdoctoral Fellowship – Cancer Biology (University of California – San Francisco)

Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania School of Medicine)

Postdoctoral Researcher – Hematopoietic Stem Cell Maintenance (Baylor College of Medicine)

Postdoctoral Fellow – Hematopoietic Stem Cells and Signaling Transduction (University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia)

Postdoctoral Positions – Reprogramming and Genetic Engineering Technologies to Develop New Models of Hematopoiesis and Hematopoietic Disorders (Icahn School of Medicine)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Research Fellow – Molecular Mechanisms Regulating Transformation and Maintenance of Leukemia Stem Cells (City of Hope)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us